Globus Medical (GMED) and Its Peers Critical Review
Globus Medical (NYSE: GMED) is one of 78 publicly-traded companies in the “Medical Equipment, Supplies & Distribution” industry, but how does it contrast to its competitors? We will compare Globus Medical to related companies based on the strength of its analyst recommendations, valuation, risk, profitability, dividends, institutional ownership and earnings.
This table compares Globus Medical and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Globus Medical Competitors||-434.44%||-44.47%||-12.99%|
This is a breakdown of recent ratings and recommmendations for Globus Medical and its competitors, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Globus Medical Competitors||211||1198||2609||84||2.63|
Globus Medical presently has a consensus price target of $36.83, indicating a potential downside of 5.82%. As a group, “Medical Equipment, Supplies & Distribution” companies have a potential upside of 6.92%. Given Globus Medical’s competitors stronger consensus rating and higher possible upside, analysts clearly believe Globus Medical has less favorable growth aspects than its competitors.
Insider & Institutional Ownership
72.2% of Globus Medical shares are owned by institutional investors. Comparatively, 65.6% of shares of all “Medical Equipment, Supplies & Distribution” companies are owned by institutional investors. 28.2% of Globus Medical shares are owned by insiders. Comparatively, 12.0% of shares of all “Medical Equipment, Supplies & Distribution” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Earnings & Valuation
This table compares Globus Medical and its competitors gross revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Globus Medical||$563.99 million||$104.34 million||35.55|
|Globus Medical Competitors||$975.11 million||$120.37 million||231.61|
Globus Medical’s competitors have higher revenue and earnings than Globus Medical. Globus Medical is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
Volatility & Risk
Globus Medical has a beta of 0.58, suggesting that its stock price is 42% less volatile than the S&P 500. Comparatively, Globus Medical’s competitors have a beta of 0.94, suggesting that their average stock price is 6% less volatile than the S&P 500.
Globus Medical competitors beat Globus Medical on 8 of the 13 factors compared.
Globus Medical Company Profile
Globus Medical, Inc. (Globus) is a medical device company focused on the design, development and commercialization of musculoskeletal implants that promote healing in patients with spine disorders. The Company is focused on implants that promote healing in patients with spine disorders. The Company’s products fall into one of two categories: Innovative Fusion or Disruptive Technologies. The Company sells its products through exclusive sales force in the United States, as well as within North, Central & South America, Europe, Asia, Africa and Australia. The sales force consists of direct sales representatives and distributor sales representatives employed by exclusive independent distributors.
Receive News & Ratings for Globus Medical Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Globus Medical Inc and related companies with MarketBeat.com's FREE daily email newsletter.